Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
about
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyThe evolution of anticoagulant therapyThe Importance of Thrombin in Cerebral Injury and DiseaseDrug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and ChallengesThe pharmacological landscape and therapeutic potential of serine hydrolasesAn update on recent patents on thrombin inhibitors (2010 - 2013)Thrombocytopenia induced by dabigatran: two case reportsA review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risksUse of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients.Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.Global assays and the management of oral anticoagulation.Enhanced elimination of dabigatran through extracorporeal methods.Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.New insights into the mechanisms of venous thrombosis.Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran.The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patientsThe modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stayA Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran.Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old AgentsWest Nile virus drug discovery.New anticoagulants for prevention of stroke in patients with atrial fibrillation.Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.Gastrointestinal disorders and dabigatran.New oral anticoagulants: comparative pharmacology with vitamin K antagonists.Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.Pharmacology of the new target-specific oral anticoagulants.Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism.Small molecule inhibitors in the treatment of cerebral ischemia.Dabigatran etexilate for venous thromboembolism: a safety evaluation.Novel anticoagulants for stroke prevention in patients with atrial fibrillation.Dabigatran excess: case report and review of the literature.Management of hemorrhage with the target-specific oral anticoagulants.New oral anti-coagulants: Implications for neurosurgery.Modulatory Role of Nurr1 Activation and Thrombin Inhibition in the Neuroprotective Effects of Dabigatran Etexilate in Rotenone-Induced Parkinson's Disease in Rats.Update on Anticoagulation: What the Interventional Radiologist Needs to Know.New oral anticoagulants: a practical guide for physicians.
P2860
Q26766303-A85EE465-E60E-4363-8889-48603C1BC280Q26771859-72080C7B-0BF3-4986-86D9-0D11BAABD051Q26772131-57FF8785-A324-48FC-9729-B57F73AEBB76Q26798105-5097D8E3-3DA0-473A-AA06-FA913A5C8A8FQ26995817-4A0EFE5D-DB18-4B59-8B03-084F22D8376EQ28299898-31915F13-4471-4F86-BF2F-CD312FE6C227Q32179630-3418A44A-902C-4481-99CA-4E7A28CC84E6Q33949244-B6BF2141-07EC-41AC-8B56-31198E602572Q34351204-D372118E-386B-468D-9AD2-397E8EC11E0AQ34917680-9E4B89DB-7F82-41A2-A755-7453B410F7E3Q35164902-45699B7F-C64C-4C70-A263-63619CC6BB0EQ35210137-10A6E1D7-C444-41E9-8A8D-4F474B0E3180Q35683869-12532C61-C907-4271-AD6D-3AD57823323DQ36068279-C8E1CB31-A164-4345-83CD-248A555FE525Q36354208-CE056F44-63AF-4D63-938E-F52F2169ED02Q37014482-F71EBE9E-18B2-4878-A541-279A4999F6CCQ37063974-F181BB53-C561-4E9E-8E3F-1BB8EAD49001Q37083546-20906898-7D3F-46F2-874A-54142E2234FFQ37444709-8E311656-9425-49FE-AB38-A03923A6E57BQ37495788-206F467F-3BC0-41C8-A985-526DD04A52C7Q37666750-E0818B06-BDA8-47DC-B268-4E2778B499D6Q37888758-DE032446-B416-439F-9184-C914C7F7DBB3Q37903926-6DE84290-38E2-4157-81EC-56598F8DB60CQ38011969-D13A8A14-CE14-41D8-B93E-9040926E894EQ38041636-15B328DC-1C41-41C3-A0A6-6643B5142B76Q38071973-4F22125E-78FC-4970-B393-8CE3D5746B10Q38079779-BA927934-7F63-4012-B0B1-2375D4DA3E0EQ38101845-19415609-CFBF-4E87-99F9-FCDA7A8B3706Q38104314-5FCD25B4-3F5C-4B2C-87AC-5FE14BA9305BQ38116784-E62ED974-AB85-4396-B04D-1D5D1C33CDDEQ38119535-29FABDF3-0225-452D-A841-9B9BA529EE72Q38184644-34592EC3-6F32-426A-8AF9-405153BB3D1AQ38193599-A3AC28E4-939C-46B8-9F4A-43C749310A24Q38212962-9F851DC6-36AF-4F7E-B7A5-632BD157B3CFQ38241091-7B305798-6D40-45B2-92B3-28779863CBFDQ38254250-3817140D-671F-44EE-B777-2B599C03C1D8Q38336863-F580C904-C8F5-4105-BE3D-77D5DB5E3F8DQ38701175-427A538F-E8E2-42C2-BADB-0100C0E8323CQ38849824-714828AC-AE76-442A-AAB2-BB4A8B59EEDCQ38930008-A0A3304B-9C3F-4D9A-B577-DA3FB5BF4BCB
P2860
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
@en
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
@nl
type
label
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
@en
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
@nl
prefLabel
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
@en
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
@nl
P2093
P1476
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
@en
P2093
Andreas Clemens
Joachim Stangier
Joanne van Ryn
Norbert Hauel
Wolfgang G Eisert
Wolfgang Wienen
P304
P356
10.1161/ATVBAHA.110.203604
P407
P577
2010-07-29T00:00:00Z